These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 10354862

  • 1. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R, Rouse MS, Piper KE, Steckelberg JM.
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R, Rouse MS, Piper KE, Steckelberg JM.
    Diagn Microbiol Infect Dis; 2000 Nov; 38(3):177-9. PubMed ID: 11109018
    [Abstract] [Full Text] [Related]

  • 3. Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong.
    Ho PL, Ng TK, Yung RW, Que TL, Yip EK, Tse CW, Yuen KY.
    J Antimicrob Chemother; 2001 Oct; 48(4):590-2. PubMed ID: 11581246
    [No Abstract] [Full Text] [Related]

  • 4. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
    Patel R, Rouse MS, Piper KE, Cockerill FR, Steckelberg JM.
    Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
    [Abstract] [Full Text] [Related]

  • 5. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
    Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, Hutchinson DK, Barbachyn MR, Brickner SJ.
    Antimicrob Agents Chemother; 1996 Apr; 40(4):839-45. PubMed ID: 8849237
    [Abstract] [Full Text] [Related]

  • 6. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
    Dowzicky MJ, Chmelařová E.
    Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
    [Abstract] [Full Text] [Related]

  • 7. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.
    Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A.
    J Antimicrob Chemother; 2000 Dec; 46(6):931-40. PubMed ID: 11102412
    [Abstract] [Full Text] [Related]

  • 8. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
    Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
    [Abstract] [Full Text] [Related]

  • 9. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
    Sweeney MT, Zurenko GE.
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
    [Abstract] [Full Text] [Related]

  • 10. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.
    Johnson AP, Warner M, Livermore DM.
    J Antimicrob Chemother; 2000 Feb; 45(2):225-30. PubMed ID: 10660506
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
    Metallidis S, Chatzidimitriou M, Nikolaidis P, Tsona A, Bisiklis A, Kollaras P, Tsiakiri E, Koumentaki E, Alexiou-Daniel S.
    J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
    [Abstract] [Full Text] [Related]

  • 12. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW.
    Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of the oxazolidinone compounds linezolid (PNU-100766) and eperzolid (PNU-100592) against middle ear isolates of Streptococcus pneumoniae.
    Kearney JA, Barbadora K, Mason EO, Wald ER, Green M.
    Int J Antimicrob Agents; 1999 Jul; 12(2):141-4. PubMed ID: 10418759
    [Abstract] [Full Text] [Related]

  • 14. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE, Tenover FC.
    Microb Drug Resist; 2003 Jul; 9(4):389-93. PubMed ID: 15000746
    [Abstract] [Full Text] [Related]

  • 15. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE, Fritsche TR, Sader HS, Jones RN.
    Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
    [Abstract] [Full Text] [Related]

  • 16. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.
    Chien JW, Kucia ML, Salata RA.
    Clin Infect Dis; 2000 Jan; 30(1):146-51. PubMed ID: 10619743
    [Abstract] [Full Text] [Related]

  • 17. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ, Hershberger E, Moldovan T, Grucz RG.
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [Abstract] [Full Text] [Related]

  • 18. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.
    Kaatz GW, Seo SM.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):799-801. PubMed ID: 8851617
    [Abstract] [Full Text] [Related]

  • 19. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
    Munckhof WJ, Giles C, Turnidge JD.
    J Antimicrob Chemother; 2001 Jun; 47(6):879-83. PubMed ID: 11389123
    [Abstract] [Full Text] [Related]

  • 20. In vitro susceptibility to methicillin, vancomycin and linezolid of staphylococci isolated from bloodstream infections in eastern Turkey.
    Tekin A, Dal T, Deveci Ö, Tekin R, Özcan N, Atmaca S, Dayan S.
    Braz J Microbiol; 2014 Jun; 45(3):829-33. PubMed ID: 25477914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.